AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05668611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Screening Phase
Description: Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of one month. A minimum total of 400 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants (at least 5 participants per day). At the end of each screen, the trainees will interpret the screen as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks.
Study NCT05668611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary Training Phase
Description: Each Primary Trained MOH Nurse will train 3 other nurses from their Health Center using pre-recorded PowerPoints.
Study NCT05668611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary Assessment Phase
Description: The secondarily trained nurses will be assessed and certified by the nurse trainer.
Study NCT05668611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary Screening Phase
Description: Following certification, the certified MOH nurses will integrate echocardiographic screening into the routine workflow at the 4 HCIII/IV clinics with each nurse carrying out screening at the assigned HC on patients (aged 5-40) presenting to the health center for routine care.~Screening will be done daily over a period of two months. A minimum total of 1200 participants will be screened during this period; each nurse will screen as many patients as they can, with a minimum of 100 participants. At the end of each screen, the trainees will interpret the study as screen negative or screen positive. They will go ahead to refer participants identified as screen positives to the district hospital (LRRH) for a confirmatory echo.~At the end of each screening day, all images will be uploaded to a cloud server for a confirmatory review by a cardiology fellow or cardiology attending physician, within in 1 - 2 weeks.
Study NCT05948865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO301
Description: Administered by intravenous injection
Study NCT05423860 — intervention group
Intervention type: OTHER
Intervention: no interventions will be performed (observational)
Description: Not applicable. (no interventions will be performed with this observational study
Study NCT06088602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoneurolysis
Description: Local anesthesia is injected in the skin. The superficial genicular nerves, more specifically the ISN and the AFCN, are visualized. A nerve stimulator is used to verify the visualized nerves., 2-3 ml of ropivacaine 5 mg/ml is injected around the nerves. After 5-15 minutes the effect is evaluated by assessing pain in the surgical area and asking the patient whether there is a pain relief. Following this evaluation, cryoneurolysis (Cryo-S, Metrum Cryoflex, Blizne Laszczynskiego, Poland) is performed unilaterally along a treatment line, the location of which was guided by visualization and palpation of anatomic landmarks. The ISN treatment line is located along the line that connects a point located 5 cm medial to the lower pole of the patella and a point located 5 cm medial to the tibial tubercle. The AFCN treatment line is located at one-third the length of the distance from the center of the patella to the top of the femur, with a width equal to the width of the patella.
Study NCT06088602 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The exact same procedure as in the cryo-group is performed, except that the nerves are not frozen with the cryoneurolysis apparatus. Sound effects from the machine are replicated to give the patient the same experience as in the active intervention group.
Study NCT04858464 — intervention group
Intervention type: OTHER
Intervention: Survey study
Description: Patients will complete the mentioned questionnaires.
Study NCT05732389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a highly selective fully humanized, IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1) (17). PD-1 is an inhibitory receptor expressed on the surface of T-cells, B cells, macrophages, and NK cells. Endogenous binding of PD-1 with one of its two ligands PD-L1 and PD-L2 results in production of an inhibitory signal which results in reduction of T-cell proliferation, cytokine production, and cytotoxic activity. This results in significant dampening of the immune response. Nivolumab acts to selectively block the receptor activation of PD-L1 and PD-L2, resulting in a release of PD-1 mediated inhibition of the immune response.
Study NCT05732389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a fully humanized monoclonal anti-CTLA-4 antibody that acts as an antineoplastic ICI by selectively binding to cytotoxic T-lymphocyte-associated antigen 4, a molecule located on the surface of cytotoxic T-cells, suppressing the immune response (17). Ipilimumab blocks CTLA-4, leading to a continuously active immune response in malignant cells.
Study NCT04672707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 32 mg
Study NCT04672707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 48 mg
Study NCT04672707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 64 mg
Study NCT04672707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromhexine Hydrochloride Tablet
Description: 80mg
Study NCT05120921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manual Treatment
Description: includes touch, joint manipulations, stretching and massage
Study NCT05120921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-management
Description: Providing rehabilitative exercises to patients to do at home
Study NCT05120921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reassurance
Description: Reassuring patients on their symptoms, diagnosis and prognosis.
Study NCT05120921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsychosocial management
Description: Giving a central place to the patient in the decision-making to help them to get back to valued activities.
Study NCT05168501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebreathing procedure
Description: Paired Duffin's rebreathing procedures performed two different isoxic end tidal PO2 levels (i.e., hyperoxic and hypoxic conditions) will be performed on Day 1 at 0, 2, 4, 6, and 24 hours.
Study NCT05622409 — intervention group
Intervention type: OTHER
Intervention: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Description: A Taiwanese Oncogenetic Panel and Integrated Clinical Data Registry Study for Diffuse Glioma
Study NCT05690659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device and exercise
Description: cavitation ultrasonic device therapeutic exercise guided ultrasonography imaging
Study NCT05607628 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Animal Protein Meals
Description: Consume reduced calorie ready meals with animal proteins to substitute participants' two main meals/day plus a serving of malted beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
Study NCT05607628 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Low Calorie Plant Protein Meals
Description: Consume reduced calorie ready meals with plant proteins to substitute participants' two main meals/day plus a serving of soy-based plant protein beverage to be consumed every day for a period of 16 weeks. Additional supervised exercise regime made up of 2 hours of resistance training plus 1 hour of aerobic training per week for a period of 16 weeks.
Study NCT05253001 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: smartphone
Description: Use the mobile chatbot approach for intervention groups to improve prenatal education.
Study NCT05253001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone
Description: Use the mobile chatbot approach for intervention groups to improve prenatal education.
Study NCT04548843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow mobilization
Description: During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.~A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis
Study NCT04548843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis
Study NCT04548843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNV-BM-PLC infusion
Description: The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.~The dosing interval between patients will be at minimum 2 weeks.
Study NCT05705635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for injection (Albumin-bound)
Description: Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
Study NCT05705635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere
Description: Taxotere, by intravenous infusion, every 3 weeks.
Study NCT04638244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Brief Online Music
Study NCT04638244 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reading messages
Description: Reading psychoeducational messages
Study NCT05289401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided blocks
Description: Ultrasound Guided Erector Spinae Plane Block Versus Ultrasound Guided Caudal Block in Pediatric
Study NCT05659537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC
Study NCT05561205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation
Study NCT05561205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: methylphenidate
Study NCT05787600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhyal rinse
Description: Filming mouthwash formulation, enriched with Hydrogen Peroxide and Hyaluronic Acid Subjects will then be given the test intervention, Perhyal rinse, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Study NCT05787600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Subjects will then be given Chlorhexidine 0.12%mouthwash, as an active comparator, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Study NCT05787600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given the nonactive control, distilled water, and will be asked to rinse with 10 ml of undiluted mouthwash for 60 s twice per day (30 min after tooth brushing) and will be instructed to refrain from eating and drinking for 30 min after rinsing. participants will be received a toothbrush with medium-hardness bristles and a toothpaste (COLGATE). No modifications to the participants' tooth brushing technique will be permitted. Next, the participants will be re-evaluated after 14 days.
Study NCT05254145 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next Generation Sequencing
Description: During the participants surgical procedure, a total of 3 ml of synovial fluid (joint fluid collected from the knee) will be collected per joint. Upon collection, the samples will be deidentified, stored on ice and shipped with a study ID number to MicroGenDx for Next Generation Sequencing.
Study NCT05583513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MLHFQ (Minnesota Living with Heart Failure Questionnaire)
Description: The MLHFQ, a 21-item HF-specific questionnaire, was adopted to evaluate the quality of life of the study subjects with score ranging 0-105 and lower the scores the better QoL
Study NCT05583513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: KCCQ (the Kansas City Cardiomyopathy Questionnaire)
Description: The KCCQ, is a 23-item self-administered questionnaire developed to independently measure the patient's perception of their health status, with score ranging 1-100 and higher scores the better QoL
Study NCT06492499 — intervention group
Intervention type: PROCEDURE
Intervention: Zero-Fluoroscopy Radiofrequency Catheter Ablation
Description: Patients undergo zero-fluoroscopy RFCA for atrioventricular nodal reentrant tachycardia (AVNRT) using the superior vena cava (SVC) or inferior vena cava (IVC) approach. The procedure is performed under conscious sedation and local infiltration anesthesia. A large-tip electrode catheter is used for mapping and ablation, guided by the EnSite NavX system, with ablation parameters set at 40 W power and 50°C temperature.
Study NCT05922670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Behavioral Health-Works Suicide Prevention Program for Sexual and Gender Minority Youth
Description: BH-Works is a web-based, comprehensive program for suicide prevention. The BH-Works program is a systems-level intervention that provides tools and resources to make organization adoption more feasible.
Study NCT06298942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural band
Description: to use the round ligament as a natural band in stead of synesthetic band with sleeve gastrectomy
Study NCT06298942 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: silicone band
Description: to use synesthetic band with sleeve gastrectomy
Study NCT05014737 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: this is an abservational study and no intervention will be involved
Study NCT05525598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One step at a time
Description: \[see 'arms' section for full description\]
Study NCT05525598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Get started
Description: \[see 'arms' section for full description\]
Study NCT05784285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in a 8-week community-based activity program
Description: Participants engage in a 8-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 8 weeks - the actual intervention phase.
Study NCT04901962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JOBST® Confidence compression garments
Description: JOBST® Confidence (JC) compression garments will be used for daytime treatment of leg or arm lymphedema. JC compression garments exert a specific therapeutic external, physical compression level and are therefore intended to use for the management of edema. JC comprise non-invasive medical devices with no direct contact with injured skin or mucous membranes and are intended for use on intact skin only.
Study NCT04810689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xuanfei Baidu Granules
Description: Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake
Study NCT04810689 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake
Study NCT06433674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Sulfate
Description: The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
Study NCT04955600 — intervention group
Intervention type: OTHER
Intervention: Implementation Study
Description: Implementation of digital technology in two different care settings from both patients, informal caregivers, and healthcare professional's perspective.
Study NCT04754217 — intervention group
Intervention type: DEVICE
Intervention: VAVGJ
Description: Replacement of the aortic valve and ascending aorta
Study NCT04754217 — intervention group
Intervention type: DEVICE
Intervention: CAVGJ
Description: Replacement of the aortic valve and ascending aorta
Study NCT06471387 — intervention group
Intervention type: BEHAVIORAL
Intervention: Flexiquit Smoking Cessation Intervention
Description: Participants will enter a 6-week (once weekly) self-delivered computerized intervention program called Flexiquit. Developed and validated by Clinical Psychologists of the Department of Psychology at the University of Cyprus, Flexiquit is an avatar-led app designed to support smoking cessation. It aims to assist with abstinence and monitor participants' progress through personalized modules and assessments.
Study NCT05049317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic FTME surgery
Description: Nerve plane was defined as the overlying tiny membranous tissue including the nerves, the adipose tissue and the extremely tiny capillaries around the nerve. Following the TME principles, the surgical procedure of FTME was guided by the nerve plane and dissected between the proper fascia of the rectum and nerve plane (the first gap), which could ensure completeness of the nerve plane and the proper fascia of the rectum.
Study NCT06089096 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Home Sleep Apnea test (HSAT)
Description: Patient will received HSAT at baseline
Study NCT04136782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel combined with carboplatin
Description: Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
Study NCT05771870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Description: Mentoring is a support network in which a more talented or experienced individual serves as a role model for a less talented individual in order to encourage professional and personal growth. Mentoring improves students' learning, abilities, and self-efficacy while decreasing stress and anxiety in nursing students through more effective communication, collaborative learning, and critical thinking.~After understanding about the study, two master's degree students from Karabük University Institute of Graduate Studies of Child Health and Diseases Nursing consented to participate on a volunteer basis and became peer mentors in the study. All postgraduate students are pediatric nurses with at least two years of clinical experience who have completed their undergraduate nursing program.
Study NCT06433674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water
Description: The placebo group with will receive a similar amount of sterile water in a colored syringe